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The human tyrosinase gene is about 50 kb long and is composed of 5 exons and 4 introns, whereas tyrosinase messenger RNA (mRNA) is B2 kb long (genebank access number NM_000372). The nascent chain of the newly synthesized tyrosinase protein is glycosylated, folded in the endoplasmic reticulum (ER), and directed to melanosomes, the organelles residing within melanocytes where melanin synthesis takes place (Park and Yaar, 2012) . Tyrosinase spans the melanosomal outer membrane and has three domains: an inner melanosomal domain that contains the catalytic region of the enzyme, a short melanosomal transmembrane domain, and a cytoplasmic domain. The cytoplasmic domain is composed of a B30 amino acids, and it is required to properly traffick tyrosinase into melanosomes (Beermann et al., 1995) .
Two types of melanin are synthesized within melanosomes: eumelanin and pheomelanin. Eumelanin is dark, brownblack, and insoluble, whereas pheomelanin is light, red-yellow sulfur-containing, and soluble. Tyrosinase is the rate-limiting enzyme in melanin biosynthesis. It catalyzes the conversion of tyrosine through oxidation to L-dihydroxyphenylalanine and requires copper for its activation. Inhibition of this oxidation reaction blocks melanin synthesis (Park and Yaar, 2012) . Hydroquinone, the most frequently used drug to treat hyperpigmentation in the United States, is a pseudosubstrate for tyrosinase, thus inhibiting tyrosinase activity.
The final steps in cutaneous pigmentation are the transfer of melanin-containing melanosomes from melanocytes to neighboring keratinocytes, and their dispersion within keratinocytes. Proper dispersal of melanosomes is required for normal skin color and for protective pigmentation. Melanosomes are phagocytosed by keratinocytes, which is facilitated by a seven-transmembrane G protein-coupled receptor called protease activated receptor-2 (PAR-2). PAR-2 is present on the keratinocyte membrane and is activated by serine proteases that cleave the extracellular portion of the receptor, exposing a new segment that acts as a tethered (attached) ligand, increasing keratinocyte phagocytic activity (Nystedt et al., 1994) .
Regulating tyrosinase expression and/or activity
A key transcription factor for tyrosinase is the microphthalmia-associated transcription factor (MITF) that, when upregulated, increases tyrosinase expression. MITF has also been intimately linked with melanocyte survival (Park and Yaar, 2012) ; thus, the effects of MITF extend beyond melanogenesis per se. Alpha-melanocyte-stimulating hormone (a-MSH), one of the first recognized positive regulators of mammalian pigmentation, upregulates the expression of MITF (Lerner, 1999) . When a-MSH binds to its melanocortin 1 receptor (MC1R), the intracellular level of cAMP is elevated through the activation of the membrane-associated adenylate cyclase enzyme (Figure 1) . The cAMP-dependent protein kinase A (PKA) enzyme is then activated, translocates to the nucleus, and phosphorylates the cAMP responsive element-binding protein (CREB). CREB then binds its DNA consensus sequence CRE in the promoter region of the MITF gene, inducing MITF transcription.
PKC constitutes a family of at least 12 isoforms, among which PKC-b has been shown to be involved in regulating tyrosinase activity. PKC is a serine/threonine kinase that resides as an inactive enzyme in the cytoplasm. It is activated by diacylglycerol (DAG), a component of the plasma membrane that is cleaved and released from the membrane during the activation of certain cell surface receptors. DAG is also released from the membrane by UV irradiation (Figure 1 ). DAG induces PKC translocation from the cytoplasm to membranes, and PKC then catalyzes the phosphorylation of serine/threonine residues on target proteins such as tyrosinase. Specifically, PKC-b phosphorylates serine residues on the cytoplasmic domain of tyrosinase, thus activating it (Park et al., 1999) . The critical role of PKC in melanogenesis was first suggested by the observation that the addition of DAG, the endogenous activator of PKC, to cultured human melanocytes rapidly increased their total melanin content; this increase was blocked by a PKC inhibitor. Moreover, topical applications of DAG to guinea pig skin increases epidermal melanin content (Park and Yaar, 2012) .
In melanocytes, PKC-b is found in close proximity to the melanosome membrane. Whereas structural differences among PKC isoforms may contribute to their associations with specific subcellular fractions, receptors for activated C-kinase (RACK), which are specific for each PKC isoform, control the translocation of PKC isoforms to specific cellular compartments. RACK-I is the receptor for activated PKC-b, and in human melanocytes the activated PKC-b/RACK-I complex translocates to the melanosome membrane to allow tyrosinase phosphorylation, thus modulating tyrosinase function at the post-translational level (Figure 1 ).
Diacylglycerol kinase-z (DGK-z) presents a novel therapeutic target to modulate pigmentation. Kawaguchi et al. (this issue, 2012) demonstrate that DGK-z is involved in tyrosinase protein degradation at the post-translational level. Specifically, the investigators show that DGK-z is the most abundant DGK isoform expressed by human melanocytes. DGK-z, which is phosphorylated by DAG, appears to affect tyrosinase function independently of PKC-b. Furthermore, inhibition of DGK-z by small interfering RNA significantly reduces melanin content, tyrosinase activity, and tyrosinase protein levels, whereas tyrosinase and MITF mRNA levels remain unchanged. Conversely, overexpression of DGK-z increases the level of tyrosinase protein, but not of tyrosinase mRNA. Protease inhibitors partially block DGK-z's effect, suggesting that DGK is a protease or that it acts by activating proteases. The investigators conclude that DGK-z regulates melanogenesis by modulating the post-translational processing of tyrosinase, specifically protein degradation (Figure 1 ). These findings further suggest that isoform-specific DGK-z inhibitor(s) have the potential to modulate human pigmentation.
Melanogenic inhibitors
Although the existence of endogenous melanogenic inhibitors has been long speculated, few of these molecules have been identified. One group of inhibitors , which then phosphorylates serine residues on tyrosinase, activating the enzyme. In addition, DAG phosphorylates diacylglycerol kinase-z (DGK-z), which regulates tyrosinase degradation. UV also damages cellular DNA, initiating a cascade of DNA damage responses including p53 activation, and leading to increased tyrosinase transcription. UV irradiation, by decreasing the level of bone morphogenetic protein (BMP) receptors, prevents BMP-4-mediated inhibition on melanogenesis. ER, endoplasmic reticulum; P, phosphate group; RACK-I, receptors for activated C-kinase.
includes sphingolipids, a class of membrane-associated lipids that act as signal transducers. Sphingolipids decrease melanogenesis, at least partly by enhancing MITF degradation via ubiquitin-meditated pathways. Another melanogenic inhibitor, bone morphogenetic protein-4 (BMP-4), downregulates tyrosinase expression in melanocytes, also partly via its effects on MITF. Interestingly, physiological doses of UV radiation, a potent melanogenic stimulator, decrease the expresion of BMP receptors on melanocytes (Yaar et al., 2006) , presumably eliminating BMP's inhibitory effect during UV-induced tanning. Mice engineered to overexpress the BMP antagonist noggin have a darker coat color and a higher eumelaninto-pheomelanin ratio compared with wild-type mice (Sharov et al., 2005) .
UV and tyrosinase function
UV is a potent inducer of pigmentation or tanning. It increases the level of a-MSH, DAG, and other compounds that activate melanogensis, and concomitantly it decreases the level of melanogenic inhibitors such as BMP. Furthermore, UV-induced DNA damage also appears to stimulate melanogenesis in pigment cells (Eller et al., 1996) . Interestingly, the action spectrum for tanning is virtually the same as that for the formation of thymine dimers, and treatment of melanocytes with agents that act exclusively by damaging DNA (unlike UV, which has multiple cellular targets) also stimulates melanogenesis. In addition, treating cells with DNA fragments such as thymine dimers can induce cellular responses that mimic DNA damage responses and result in tanning (Eller and Gilchrest, 2000) . Moreover, p53, a tumor suppressor protein and transcription factor that is induced and activated by UV radiation, upregulates tyrosinase mRNA and protein. In p53 knockout mice, UV radiation stimulates melanogenesis of the ears only minimally compared with the far greater ''tanning'' response in p53 wild-type mice (Khlgatian et al., 2002) . Thus, tanning may be viewed as part of a p53-mediated DNA damage-adaptive cellular response enabling the skin to withstand subsequent exposures to UV radiation.
Clinical implications
Although multiple pathways that modulate tyrosinase expression and/or activity have been identified, few treatment modalities for pigmentary disorders exist (Table 1) . Some molecules inhibit tyrosinase activity, but their effects are largely nonspecific, and they interfere with other proteins as well. Similarly, few agents stimulate tyrosinase activity. The data presented by Kawaguchi et al., (2012) , complementing and expanding previous work, elucidate novel molecules and pathways in the pigmentary process. Taking this work in to account, future therapeutic modalities could be developed to affect pigmentary disorders and provide options for sunless tanning. Chemical peels and different lasers are also used for treatment of hyperpigmentary disorders but are beyond the scope of this commentary.
